Lyrica Generics Likely Delayed By A Pfizer Labeling Supplement
Executive Summary
US FDA's last-minute approval may have allowed Pfizer three more weeks of sales without competition.
You may also be interested in...
ANDA Sponsors Need US FDA Permission To Avoid Last-Minute Label Update Delays
Under changes in the 2022 appropriations bill, generic drug applications can be approved even if a last-minute labeling update is needed, but sponsors risk product misbranding if the CBE is late.
ANDA Sponsors Need US FDA Permission To Avoid Last-Minute Label Update Delays
Under changes in the 2022 appropriations bill, generic drug applications can be approved even if a last-minute labeling update is needed, but sponsors risk product misbranding if the CBE is late.
Generic Drug Sponsors Would Get More Info On Brand Inactive Ingredients Under User Fee Bill
PhRMA expresses concerns the provision would reveal trade secrets, but since the draft bill already has support from the Republican committee leadership, the brand industry may find it a challenge to get the language removed.